Portfolio Archive

Covagen AG

Covagen develops next generation protein drugs for the treatment of inflammatory diseases and cancer by using its proprietary protein engineering technology, which has been developed at ETH Zurich. Covagen's innovative platform comprises the recently developed Covalent DNA Display technology and a novel single domain protein scaffold, which – in analogy to antibodies – can be engineered to yield high affinity binding proteins called Fynomers that can be used for therapeutic applications. In addition, the modular structure of Covagen's Fynomers and their favorable biophysical properties potentially allow for treatment modalities that are difficult or impossible to be exploited with antibodies. MPH participated in Covagen’s seed financing round in October 2009. For more information, please visit www.covagen.com.

Ferrokin Biosciences, Inc.

FerroKin Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a next generation iron chelator for the treatment of iron-overload in patients with transfusion-dependent anemia. MPH participated in Ferrokin’s Series A financing round in December 2008 and Series B financing round in July 2010. FerroKin was acquired by Shire plc in March 2012. For more information, please visit www.ferrokin.com.

Genocea Biosciences

Genocea Biosciences is developing novel vaccines against various infectious diseases using its proprietary platform for the rapid discovery of T-cell antigens. Its lead programs include HSV2, Streptococcus pneumoniae, and Chlamydia trachomatis. MPH participated in Genocea's Series B financing round in January 2011. For more information, please visit www.genocea.com.

Intradigm Corporation

Intradigm Corporation is a biotechnology company committed to the development of RNA interference (RNAi) therapeutics for the treatment of serious disease. The Company’s expertise in drug development and delivery serves as the foundation of its RNAi platform. In particular, the Company’s novel and proprietary RNAi nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product. The Company is based in Palo Alto, California. MPH participated in Intradigm’s Series B financing round in September 2008. Intradigm merged with Silence Therapeutics (LSE:SLN) in December 2009. For more information, please visit www.silence-therapeutics.com.

PharmEste S.r.l.

PharmEste S.r.l. is developing its proprietary small molecule TRPV1 (transient receptor potential vanilloid 1) antagonists for the treatment of neuropathic pain, overactive bladder and other sensory neuron-mediated diseases. Their lead project is in phase I clinical testing. Pharmeste is located in Ferrara and Milan, Italy. MPH participated in Pharmeste’s Series B financing round in October 2008. For more information, please visit www.pharmeste.com.


Syndexa is developing novel drugs targeting the interface between inflammatory and metabolic pathways. With its proprietary screening technologies targeting ER adaptive responses, Syndexa has identified lead molecules for the treatment of various diseases including type 2 diabetes, obesity and cardiovascular disease. Syndexa is based in Watertown, MA. MPH participated in Syndexa's Series B1 financing round in January, 2012. For more information, please visit www.syndexa.com.